Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Other OTCTotal Valuation
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited carries a market capitalization of 6.20B, placing it among publicly traded companies globally. Its enterprise value stands at 32.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.20B |
| Enterprise Value | 32.10B |
Share Statistics
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited currently has 1.63B shares outstanding.
| Shares Outstanding | 1.63B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited trades at a trailing price-to-earnings ratio of 9.27. The price-to-sales ratio is 0.34, and the price-to-book ratio stands at 1.03.
| PE Ratio | 9.27 |
| PS Ratio | 0.34 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 0.73 |
| P/FCF Ratio | 24.50 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited trades at an EV/EBITDA multiple of 8.50 and an EV/FCF ratio of 22.87. The EV/Sales ratio of 0.42 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.50 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.42 |
| EV / EBITDA | 8.50 |
| EV / EBIT | 8.50 |
| EV / FCF | 22.87 |
Financial Position
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited maintains a current ratio of 1.54, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.90, indicating elevated leverage, while an interest coverage ratio of 9.23 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.54 |
| Quick Ratio | 0.31 |
| Debt / Equity | 39.90 |
| Debt / EBITDA | 4.21 |
| Interest Coverage | 9.23 |
Financial Efficiency
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited posts a return on equity of 11.39 and a return on invested capital of 5.87.
| Return on Equity (ROE) | 11.39 |
| Return on Assets (ROA) | 3.49 |
| Return on Invested Capital (ROIC) | 5.87 |
| Return on Capital Employed (ROCE) | 7.33 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.75 |
Taxes
Over the trailing twelve months, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has paid 559.97M in income taxes, reflecting an effective tax rate of 16.14.
| Income Tax | 559.97M |
| Effective Tax Rate | 16.14 |
Stock Price Statistics
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's stock has gained approximately 4.93274% over the past 52 weeks. The 50-day moving average sits at 2.26, while the 200-day moving average is 2.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | 4.93274% |
| 50-Day Moving Average | 2.26 |
| 200-Day Moving Average | 2.31 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited generated 75.78B in revenue and converted that into 2.80B in net income, yielding earnings per share of 1.79. EBITDA reached 3.78B, while operating income came in at 3.78B.
| Revenue | 75.78B |
| Gross Profit | 12.38B |
| Operating Income | 3.78B |
| Pretax Income | 3.47B |
| Net Income | 2.80B |
| EBITDA | 3.78B |
| EBIT | 3.78B |
| Earnings Per Share (EPS) | 1.79 |
Balance Sheet
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited holds 11.83B in cash and equivalents against 15.89B in total debt, resulting in a net debt position of 1.02B. Total book value stands at 25.31B, with working capital of 20.38B providing operational flexibility.
| Cash & Cash Equivalents | 11.83B |
| Total Debt | 15.89B |
| Net Debt | 1.02B |
| Equity (Book Value) | 25.31B |
| Book Value Per Share | 15.56 |
| Working Capital | 20.38B |
Cash Flow
After subtracting -1.06B in capital expenditures, free cash flow totaled -1.06B - equivalent to -0.65 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -1.06B |
| Free Cash Flow | -1.06B |
| FCF Per Share | -0.65 |
Margins
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited operates with a gross margin of 16.34, reflecting its pricing power and cost economics. The operating margin of 4.98 and net profit margin of 3.70 provide insight into operational efficiency.
| Gross Margin | 16.34 |
| Operating Margin | 4.98 |
| Pretax Margin | 4.58 |
| Profit Margin | 3.70 |
| EBITDA Margin | 4.98 |
Dividends & Yields
The company's payout ratio of 58.74 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.09 |
| Dividend Yield | N/A |
| Payout Ratio | 58.74 |
| Shareholder Yield | -1.22 |
| FCF Yield | 4.08 |
Stock Splits
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's most recent stock split took place on January 28, 2014 with a 10000:10031 split ratio.
| Last Split Date | 1/28/2014 |
| Split Ratio | 10000:10031 |
Scores
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited posts an Altman Z-Score of 2.23, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.23 |